|
1
|
Burz C, Berindan-Neagoe I, Balacescu O and
Irimie A: Apoptosis in cancer: Key molecular signaling pathways and
therapy targets. Acta Oncologica. 48:811–821. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Jeong SY and Seol DW: The role of
mitochondria in apoptosis. BMB Rep. 41:11–22. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Newmeyer DD and Fergusonmiller S:
Mitochondria: Releasing power for life and unleashing the
machineries of death. Cell. 112:481–490. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Vo TT: Relative mitochondrial priming of
myeloblasts and normal HSCs determines chemotherapeutic success in
AML. Cell. 151:344–355. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Oltvai ZN, Milliman CL and Korsmeyer SJ:
Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that
accelerates programmed cell death. Cell. 74:609–619. 1993.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Chipuk JE and Green DR: How do BCL-2
proteins induce mitochondrial outer membrane permeabilization?
Trends Cell Biol. 18:157–164. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Youle RJ and Strasser A: The BCL-2 protein
family: Opposing activities that mediate cell death. Nat Rev Mol
Cell Biol. 9:47–59. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kvansakul M, Yang H, Fairlie WD, Czabotar
PE, Fischer SF, Perugini MA, Huang DC and Colman PM: Vaccinia virus
anti-apoptotic F1L is a novel Bcl-2-like domain-swapped dimer that
binds a highly selective subset of BH3-containing death ligands.
Cell Death Differ. 15:1564–1571. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wei MC, Zong WX, Cheng EH, Lindsten T,
Panoutsakopoulou V, Ross AJ, Roth KA, Macgregor GR, Thompson CB and
Korsmeyer SJ: Proapoptotic BAX and BAK: A requisite gateway to
mitochondrial dysfunction and death. Science. 292:727–730. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Li H, Zhu H, Xu CJ and Yuan J: Cleavage of
BID by caspase 8 mediates the mitochondrial damage in the Fas
pathway of apoptosis. Cell. 94:491–501. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Hamacher-Brady A and Brady NR:
Bax/Bak-dependent, Drp1-independent Targeting of X-linked inhibitor
of apoptosis protein XIAP) into inner mitochondrial compartments
counteracts smac/DIABLO-dependent effector caspase activation. J
Biol Chem. 290:220052015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Shiozaki EN, Chai J, Rigotti DJ, Riedl SJ,
Li P, Srinivasula SM, Alnemri ES, Fairman R and Shi Y: Mechanism of
XIAP-mediated inhibition of caspase-9. Mol Cell. 11:519–527. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Edison N, Curtz Y, Paland N, Mamriev D,
Chorubczyk N, Haviv-Reingewertz T, Kfir N, Morgenstern D,
Kupervaser M, Kagan J, et al: Degradation of Bcl-2 by XIAP and ARTS
promotes apoptosis. Cell Rep. 21:442–454. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yan Y, Mahotka C, Heikaus S, Shibata T,
Wethkamp N, Liebmann J, Suschek CV, Guo Y, Gabbert HE, Gerharz CD
and Ramp U: Disturbed balance of expression between XIAP and
Smac/DIABLO during tumour progression in renal cell carcinomas. Br
J Cancer. 91:1349–1357. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Bilim V, Yuuki K, Itoi T, Muto A, Kato T,
Nagaoka A, Motoyama T and Tomita Y: Double inhibition of XIAP and
Bcl-2 axis is beneficial for retrieving sensitivity of renal cell
cancer to apoptosis. Br J Cancer. 98:941–949. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Gavathiotis E, Reyna DE, Davis ML, Bird GH
and Walensky LD: BH3-triggered structural reorganization drives the
activation of proapoptotic BAX. Mol Cell. 40:481–492. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Tait SW and Green DR: Mitochondria and
cell death: Outer membrane permeabilization and beyond. Nat Rev Mol
Cell Biol. 11:621–632. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hamacherbrady A, Choe SC, Krijnselocker J
and Brady NR: Intramitochondrial recruitment of endolysosomes
mediates Smac degradation and constitutes a novel intrinsic
apoptosis antagonizing function of XIAP E3 ligase. Cell Death
Differ. 21:1862–1876. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Jost PJ, Grabow S, Gray D, Mckenzie MD,
Nachbur U, Huang DC, Bouillet P, Thomas HE, Borner C, Silke J, et
al: XIAP discriminates between type I and type II FAS-induced
apoptosis. Nature. 460:1035–1039. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Adams JM and Cory S: The Bcl-2 apoptotic
switch in cancer development and therapy. Oncogene. 26:1324–1337.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Bossy-Wetzel E, Newmeyer DD and Green DR:
Mitochondrial cytochrome c release in apoptosis occurs upstream of
DEVD-specific caspase activation and independently of mitochondrial
transmembrane depolarization. EMBO J. 17:37–49. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Thomas A, El Rouby S, Reed JC, Krajewski
S, Silber R, Potmesil M and Newcomb EW: Drug-induced apoptosis in
B-cell chronic lymphocytic leukemia: Relationship between p53 gene
mutation and bcl-2/bax proteins in drug resistance. Oncogene.
12:1055–1062. 1996.PubMed/NCBI
|
|
23
|
Pepper C, Hoy T and Bentley DP: Bcl-2/Bax
ratios in chronic lymphocytic leukaemia and their correlation with
in vitro apoptosis and clinical resistance. Br J Cancer.
76:935–938. 1997. View Article : Google Scholar : PubMed/NCBI
|
